AMOEBA (EPA:AMEBA) - European Investment Bank (EIB) provides EUR 20m credit line to Amoéba to revolutionise water treatment

Transparency directive : regulatory news

06/10/2017 17:40

JOINT PRESS RELEASE

Lyon, 6th October 2017

#InvestEU: European Investment Bank (EIB) provides EUR 20m credit line to
Amoéba to revolutionise water treatment

Amoéba, an innovative company developing a disruptive biological biocide
capable of eliminating waterborne bacterial risk (legionella, pseudomonas,
listeria, etc.) has received financing worth EUR 20m from the EIB. This EIB
financing is secured by the European Fund for Strategic Investments (EFSI), the
cornerstone of the Investment Plan for Europe, commonly known as the Juncker
Plan.

This EU financing will enable Amoéba to speed up its production capacity
whilst supporting the development of its international business. It will also
make a valuable contribution to its investments in research, development and
innovation (RDI). Amoéba aims to revolutionise water treatment via a
biological process that can protect the environment from chemical products. The
entirely natural solution proposed by Amoéba offers a more effective
alternative to the chemical treatments traditionally used in the industrial
sector. It also complies with the new regulations governing chemical emissions
into the environment. Given the scope of the worldwide market for chemical
biocides (EUR 21bn), Amoéba is initially concentrating on the segment of
industrial air-cooled towers (ACT) estimated to be worth EUR 1.7bn.

"This financing illustrates the priority we are giving to the environment and
innovation", said EIB Vice- President Ambroise Fayolle at the signing ceremony.
"It will enable Amoéba to support the development of its innovative biological
biocide, which offers an alternative to other forms of water treatment, and
increase its production capacity. This loan, which comes under the Juncker
Plan, is designed to step up our financing of small innovative businesses with
strong growth potential. It is also at the heart of the priorities of the
French Government's investment plan."

"This EIB loan shows the EU's commitment to supporting industry and innovation
in Europe. In return, Amoéba, an example of the industry of the future, will
bolster Europe's competitiveness compared with other regions. It would be
difficult to nurture new leaders without this crucial phase of investment. On
behalf of Amoéba, I wish to thank the EIB for the confidence it has placed in
our company at the pre- commercialisation stage", said Fabrice Plasson, CEO of
Amoéba.

The biological biocide developed by Amoéba is a microorganism, a natural
predator of pathogenic bacteria and reservoirs such as biofilm in which
bacteria protect themselves from chemical biocides. The product has undergone
an in-depth validation process and has been tested for a total of more than 10
years at industrial sites under real conditions.

Amoéba plans to invest massively in its production capacity to meet its
substantial customer demand and continue to nurture a distribution network that
is already well established in Europe and North America. Such growth will
undoubtedly have a social impact in terms of job creation.

With innovation as one of its key priorities, the EIB Group provided EUR 13.5bn
to innovative projects across Europe in 2016, supporting research programmes
from large groups, midcaps and smaller companies. In France in 2016, 38% of the
EIB Group's total investment of EUR 9.3bn was devoted to supporting companies,
innovation and R&D.

The Juncker Plan is continuing to gather momentum in France, with a running
total of 99 operations providing EUR 7.5bn in EIB Group financing set to
mobilise EUR 35.4bn in additional investments.

Note to editors

About the European Investment Bank (EIB)
The European Investment Bank (EIB) is the EU bank, and together with the
European Investment Fund (EIF) forms the EIB Group.

Thanks to its reliable expertise and the financial attractiveness of its AAA
rating, the EIB Group has doubled the volume of its activities in France since
2012 (reaching EUR 9.3bn in 2016), not only supporting businesses and
innovation but also financing investment in strategic sectors such as climate
action, energy, healthcare, education for young people and training
infrastructure.

About the Investment Plan for Europe
The Investment Plan for Europe, the so-called "Juncker Plan", is one of
Jean-Claude Juncker's top priorities. It focuses on boosting investments in
Europe to create jobs and growth by making smarter use of new and existing
financial resources, removing obstacles to investment and providing greater
visibility and technical assistance to investment projects.
The European Fund for Strategic Investments (EFSI) is the central pillar of the
Juncker Plan. It enables the EIB to invest in more, often riskier, projects
with high added value. EFSI is already showing concrete results. The projects
and agreements approved for financing under EFSI so far are expected to
mobilise more than EUR 225bn in investments and support around 445 000 SMEs
across all 28 Member States.

About Amoéba
Amoéba aims to become the world leader in treating the bacterial risk present
in water and human wounds. Its solutions provide an alternative to the chemical
products widely used in the water cooling sector and in wound care. On the
global chemical biocides and wound care products markets, estimated
respectively at EUR 21bn(1) and EUR 15.2bn(2), Amoéba is currently
concentrating on the segment of industrial air-cooled towers (ACT) estimated to
be worth EUR 1.7bn(3) for chemical biocides. The use of Willaertia magna C2c
Maky in the field of human health will require the approval of the FDA (Food
and Drug Administration) in the United States. BIOMEBA, Amoéba's biological
biocide for water treatment, has not yet received a marketing licence in the
US, Europe and Canada. Amoéba has already taken the necessary regulatory steps
to obtain marketing licences in these regions to use BIOMEBA in water cooling
systems. Based in Chassieu (Lyon, France), Amoéba is listed on the Euronext
Paris stock exchange - Compartment C - and joined the CAC(r) Small Index on 21
September 2015. For more information, please see www.amoeba-biocide.com.

(1) Marketsandmarkets.com, "Wound Care Market by Product, Wound Type, End User
- Global Forecast to 2021," 2016.
(2) M. Diligence, "Wound Management: An $18.5 billion+ worldwide market in
2021," MedMarket Diligence, 10 June 2013. [Online]. Available:
http://blog.mediligence.com/2013/06/10/wound-management-an-18-5-billion-
worldwide-market-in-2021/. [Accessed 14 February 2017].
(3) Amoéba data collated from the following sources: DRIRE 2013, Eurostat,
ARHIA 2013

Press contacts:

EIB:
Anne-Cécile Auguin, a.auguin@eib.org, tel.: +352 43 79 83330;
Mobile: +352 621 36 19 48
Website: www.eib.org/press; Press Office: +352 4379 21000 - press@eib.org

Follow the EIB on Twitter @eib.

Amoéba SA:
Nathalie Combrousse, nathalie.combrousse@amoeba-biocide.com,
tel.: +33 (0)4 81 09 18 15

Actifin - Financial press relations:
Ghislaine Gasparetto, ghislaine.gasparetto@actifin.fr,
tel.: +33 (0)1 56 88 11 11

source : webdisclosure.com

AMOEBA's latest news

07/10/2024 17:45

AMOEBA (EPA:AMEBA) - European Investment Bank (EIB) provides EUR 20m credit line to Amoéba to revolutionise water treatment

Transparency directive : regulatory news

AMOEBA's latest news

Other stories